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A comprehensive two-phase ‘‘hot spot’’ saturation
mutagenesis strategy for the rapid evolution of glyco-
syltransferase (GT) specificity for nonnatural accep-
tors is described. Specifically, the application of
a high-throughput screen (based on the fluorescent
acceptor umbelliferone) was used to identify key
amino acid hot spots that contribute to GT proficiency
and/or promiscuity. Saturation mutagenesis of the
corresponding hot spots facilitated the utilization of
a lower-throughput screen to provide OleD prodigy
capable of efficiently glycosylating the nonnatural
acceptor novobiocic acid with an array of unique
sugars. Incredibly, even in the absence of a high-
throughput screen for novobiocic acid glycosylation,
this approach rapidly led to improvements in the
desired catalytic activity of several hundred-fold.
INTRODUCTION
Glycosylated secondary metabolites continue to serve as an im-
portant source for the discovery of new drugs. As a key element of
these natural pharmacophores, the attached sugars are typically
critical for biological activity, and subtle alterations in natural-
product glycosylation can transform a natural agent’s pharmaco-
logical properties, its molecular and cellular specificity, and even
its mechanism of action (Ahmed et al., 2006; Thorson and Vogt,
2002; Weymouth-Wilson, 1997). ‘‘Glycorandomization’’ is an
emerging method for natural-product glycodiversification that
employs the inherent or engineered substrate promiscuity of
anomeric kinases and nucleotidyltransferases for the in vitro syn-
thesis of sugar nucleotide libraries. As the culminating step, this
diverse range of sugar donors is processed by natural-product
glycosyltransferases (GTs) to provide a library of variant natu-
ral-product glycosides (Griffith et al., 2005; Langenhan et al.,
2005). The successful glycorandomization of glycopeptides
(Fu et al., 2003), avermectins (Zhang et al., 2006a), and enediynes
(Zhang et al., 2006b) highlights the notable promiscuity displayed
by several natural-product GTs. Yet, attempts to utilize other
natural-product GTs for glycorandomization have been severely
restricted bythe catalysts’ stringent substrate specificity (Borisova
et al., 2006; Yuan et al., 2005). For example, the noviosyltransfer-Chemistry & Biologyase NovM, which catalyzes the glycosylation of novobiocic acid
(1) (Figure 1A) en route to novobiocin (8) (Figure 1D; Albermann
et al., 2003; Freel Meyers et al., 2003), was found to accept
only 4 of 54 alternative sugar nucleotides examined (Albermann
et al., 2003; Freel Meyers et al., 2003). Thus, although permissive
secondary metabolite GTs provide new opportunities for drug
discovery, the stringent specificity of others limits enzymatic
natural-product diversification and highlights a need for general
GT engineering and/or evolution platforms.
Despite a wealth of GT structural and biochemical information,
few successful applications of rational structure-based engineer-
ing to alter natural-product GT donor/acceptor specificities exist
(Hancock et al., 2006; Williams and Thorson, 2008b). Among the
most recent, a combination of sequence-guided and structure-
guided mutagenesis allowed for the modulation of the N- versus
O-glucosylation activities of xenobiotic GTs from Arabidopsis
thaliana (Brazier-Hicks et al., 2007). Alternatively, the general
lack of high-throughput GT screens/selections has also limited
the directed evolution of GTs (Williams et al., 2007; Williams
and Thorson, 2008a). As the first example in the context of natural
products, the directed evolution of the oleandomycin GT (OleD)
from Streptomyces antibioticus by using a simple fluorescence-
based screen was recently described (Williams et al., 2007;
Williams and Thorson, 2008a). Specifically, a small library of
OleD variants, screened for the ability to glucosylate the fluores-
cent surrogate acceptor 4-methylumbelliferone (4), led to a num-
ber of variants with the improved ability to produce b-D-glucopyr-
anoside (6) (Figure 1B). The functional amino mutations were
subsequently recombined to afford a triple-mutant enzyme that
displayed a marked improvement in both acceptor and donor
promiscuity. Interestingly, this variant also displayed a modest
(5-fold) improvement in glucosylation toward novobiocin aglycon
(1) (Figure 1C)—a potential starting point for circumventing the
stringency of the native noviosyltransferase NovM. Moreover,
novobiocin presents an excellent model, as the aminocoumarins
have long been known as potent bacterial type II DNA topoiso-
merase DNA gyrase inhibitors (Maxwell and Lawson, 2003) and
can also augment the activity of various anticancer agents via
their ability to inhibit Hsp90 (Marcu et al., 2000a, 2000b).
Unlike the umbelliferone 4, novobiocic acid (1) is not fluores-
cent, which severely limits the throughput of any engineering
strategy dependent upon 1 as substrate. We postulated that
the amino acid positions identified (hot spots) as contributing
to GT proficiency and/or promiscuity via the high-throughput
fluorescence-based screen (using 4) are also likely to contribute15, 393–401, April 2008 ª2008 Elsevier Ltd All rights reserved 393
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‘‘Hot Spot’’ Mutagenesis of Glycosyltransferasesto utilization of other variant substrates (e.g., 1). To test this
hypothesis, herein we describe the optimization of OleD toward
the nonnatural acceptor 1 via a comprehensive program of hot
spot saturation mutagenesis of functional positions previously
identified via the high-throughput fluorescence-based screen.
Incredibly, even in the absence of a high-throughput screen for
glucosylation of 1, this approach led to activity improvements
toward 1 of several hundred-fold. In addition, this study reveals
a correlation between catalyst proficiency and increased
donor promiscuity in the context of 1, ultimately affording a
new, to our knowledge, catalyst for the glycorandomization of
novobiocin.
RESULTS
Specificity of OleD Mutants toward Novobiocic Acid (1)
As previously described, the OleD triple mutant P67T/S132F/
A242V displayed improvements in glucosylation activity with
a panel of nonnatural acceptors, including novobiocic acid (1)
Figure 1. Relevant GT-Catalyzed Coumarin
Glycosylation Reactions
(A) The reaction catalyzed by WT NovM.
(B) The reaction employed for the fluorescence-
based screening assay used to evolve OleD.
(C) Representation of the novobiocic acid glucosy-
lation reaction catalyzed by WT and variant OleD.
(D) The structures of the representative naturally
occurring aminocoumarin antibiotics novobiocin
(8), clorobiocin (9), and coumermycin A1 (10).
(5-fold improved; Williams et al., 2007).
This variant was constructed after the
identification of three clones from a library
of OleD mutants, which had improved
activity toward umbelliferone 4. One of
these clones, 2C3, possessed a single
amino acid mutation (A242V), whereas
the other two, 8B3 and 7B9, possessed
the mutations P67T/I112T and S132F/
G340W, respectively. In order to identify
functional mutations in 8B3 and 7B9,
each single mutant was constructed by
site-directed mutagenesis, and the spe-
cific activity of each purified enzyme
toward 4 was determined (Williams
et al., 2007). These results clearly demon-
strated that P67T, S132F, and A242V
were responsible for improved activity
toward 4 (7-, 2.6-, and 2.3-fold im-
proved compared to wild-type [WT]
OleD), whereas G340W and I112T ap-
peared to be nonfunctional (0.5-fold
reduced activity, compared to WT OleD;
Williams et al., 2007). To further evaluate
the impact of these mutations on sub-
strate specificity, the activity of each
single mutant OleD was determined with
the alternative acceptor, 1 (Figure 2A).
These results revealed that P67T, S132F, and A242V increased
production of the putative glucoside 7 2- to 3-fold (Figure 2A),
whereas G339W was nonbeneficial. Surprisingly, I112T dis-
played the largest improvement (7.4-fold) in glucosylation activ-
ity toward 1. Thus, in the previously identified double mutant
P67T/I112T (clone 8B3; Williams et al., 2007), both P67T and
I112T influence 1 specificity, whereas only P67T appears to be
functional with respect to 4.
Given that I112T, P67T, S132F, and A242V individually im-
prove activity toward 1, combinations were next assessed for
synergistic enhancements of the desired activity. For this sec-
ondary set of combinations, I112T was retained as an invariant
substitution, given its significant impact on the activity of 1.
Thus, three double mutants were generated by combining
P67T, S132F, and A242V with I112T, and each double mutant
was overexpressed and purified, and the specific activity toward
the substrate pair 1/5 was determined by reverse phase-high-
performance liquid chromatography (RP-HPLC; Figure 2A).
This analysis revealed that the activity of the I112T variant could394 Chemistry & Biology 15, 393–401, April 2008 ª2008 Elsevier Ltd All rights reserved
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A242V (P67T/I112T and A242V/I112T, respectively), whereas
the S132F/I112T variant was slightly less active than the I112T
parent (Figure 2A). As predicted, further amalgamation of the
three remaining mutations, to give the triple mutant P67T/
I112T/A242V, provided a superior catalyst for 1 glucosylation.
Among the two additional triple mutants possible, I112T/
S132F/A242V was less active than P67T/I112T/A242V, consis-
tent with the detrimental effect of the S132F mutation in combi-
nation with other functional substitutions. Therefore, the remain-
ing triple mutant (P67T/I112T/S132F) was not pursued. For
Figure 2. Creation of OleD Variants Improved toward Novobiocic
Acid, 1
(A) Specific activities of WT and mutant OleDs with novobiocic acid (1) and
UDP-Glc (5) as acceptor and donor, respectively. Error bars represent
standard deviation from three independent measurements.
(B) The crude cell extract glucosylation activities of randomly selected colonies
from saturation mutagenesis libraries P67X, I112X, and A242X, with 1 as the
acceptor. Activities are illustrated in descending order, and arrows designate
clones that were selected for in-depth characterization.Chemistry & Biologyunknown reasons, the quadruple mutant P67T/I112T/S132F/
A242V failed to express under several different conditions tested
(data not shown).
Saturation Mutagenesis of Pro67, Ile112, and Ala242
To further optimize the selected lead catalyst, single-site satura-
tion mutagenesis at Pro67, Ile112, and Ala242 in the scaffold
P67T/I112T/A242V was performed, generating the libraries
‘‘P67X,’’ ‘‘I112X,’’ and ‘‘A242X,’’ respectively. A key constraint
of this approach is that, unlike the screening target in our original
directed evolution program (4), the acceptor, 1, is nonfluores-
cent. Accordingly, each library was screened for activity toward
1 via RP-HPLC, and, for convenience, we limited screening to
100 colonies from each library, which represents 95% cover-
age (Firth and Patrick, 2005). From this approach, library P67X
failed to identify improved variants, whereas several colonies
from the I112X and A242X libraries displayed 2- to 3-fold en-
hancements of 1 glucosylation (Figure 2B). DNA sequencing re-
vealed that substitution of Ala242 with leucine was responsible
for the hits identified from the A242X library, whereas two hits
from the I112X library were found to possess the mutation
I112K. Subsequent enzyme assay, with purified enzymes, con-
firmed that these clones were more active than the parent
P67T/I112T/A242V. Specifically, P67T/I112K/A242V and P67T/
I112T/A242L were 7- and 4-fold improved, respectively,
over the parent P67T/I112T/A242V (Figure 2A). While a recombi-
nation of the three ‘‘best’’ mutations (P67T/I112K/A242L) leads
to a slightly less active variant, it is notable that this approach
rapidly identified a variant (P67T/I112K/A242V) that is 150-fold
improved compared to WT OleD and 28-fold improved over
the previously described P67T/S132F/A242V (Williams et al.,
2007) in terms of specific activity with 1 and 5.
Product Characterization
All OleDs described, including WT OleD, catalyzed the formation
of a single, identical product based on RP-HPLC and liquid
chromatography-mass spectrometry (LC-MS) (data not shown),
consistent with the formation of a single monoglucoside with
conserved regio-andstereochemistry.Thearchitecturalsimilarities
between 1 and umbelliferone 4 implicate the 1 C70-OH as the
likely position for glucosylation, to provide7 (Figure 1C). Scale-up
of the P67T/I112K/A242L-catalyzed 1-glucosylation reaction
followed by structural elucidation confirmed glucoside 7 as the
product (see Experimental Procedures and Figure S1, see the
Supplemental Data available with this article online). Interest-
ingly, LC-MS analysis of this large-scale reaction also revealed
trace production of a putative diglucosyl-substituted product
(data not shown).
Kinetic Characterization of WT and Mutant OleDs
The WT and the mutant OleD P67T/I112K/A242L were com-
pared by determining steady-state kinetic parameters with 1 or
5 as variable substrates, as described in the Experimental Proce-
dures. The WT enzyme displayed hyperbolic saturation with both
1 and 5 as variable substrates, providing a KM for 1 and 5 of 2 and
2.81 mM, respectively (Figures 3A and 3B). The kcats determined
with 1 and 5 (0.041 and 0.073 min1, respectively) were not in
complete agreement, likely because at the concentration of 1
used (5 mM, the solubility limit), with 5 as variable substrate,15, 393–401, April 2008 ª2008 Elsevier Ltd All rights reserved 395
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less, these results demonstrate that 1 is a poor substrate for
WT OleD.
The steady-state kinetics of the triple mutant P67T/I112K/
A242V were very different from that of the WT enzyme (Figures
3C and 3D). Saturation with both 1 and 5 was easily achieved,
with apparent KMs of 0.8 mM and 0.41 mM, respectively, which
are 2.5-fold and 6.9-fold improved over WT OleD. Moreover, the
kcats determined with either acceptor 1 or donor 5 as the variable
substrate (5.13 and 3.67 min1) were in closer agreement, re-
flecting the improved KM for the acceptor. Thus, in terms of cat-
alytic efficiency (kcat/KM) with 1 as acceptor, the triple mutant
P67T/I112K/A242V is 300-fold improved compared to WT
OleD.
Donor Specificity of P67T/I112K/A242V
The sugar nucleotide donor promiscuity of WT and mutant P67T/
I112K/A242V OleD was probed by using RP-HPLC analysis with
a set of 20 potential ‘‘unnatural’’ UDP donors as surrogates for
UDP-Glc (5) in the presence of 1 as acceptor (Figure 4A). This
set was comprised of unnatural sugar nucleotides generated
via chemoenzymatic synthesis, representing alterations of the
sugar at C100, C200, C300, C400, or C600 (Barton et al., 2002;
Fu et al., 2003; Jiang et al., 2003). Putative product identities were
confirmed by LC-MS (Figure S2; Table S1). Of the 21 sugar nucle-
otides tested, only UDP-Glc (5), UDP-xylose (11), UDP-6-deoxy-
glucose (12), and UDP-4,6-dideoxy-glucose (18) led to detect-
able product with WT OleD, ranging from0.1%–3% conversion
in 3 hr (Figure 4B). In contrast, the optimized mutant P67T/I112K/
Figure 3. Steady-State Kinetic Analysis of
WT and P67T/I112K/A242V OleD
(A) WT OleD with novobiocic acid (1) as variable
substrate and the concentration of UDP-Glc (5)
fixed at 5 mM.
(B) WT OleD with UDP-Glc (5) as variable substrate
and the concentration of novobiocic acid (1) fixed
at 5 mM.
(C) P67T/I112K/A242V OleD with novobiocic acid
(1) as variable substrate and the concentration of
UDP-Glc (5) fixed at 5 mM.
(D) P67T/I112K/A242V OleD with UDP-Glc (5) as
variable substrate and the concentration of novo-
biocic acid (1) fixed at 5 mM.
Error bars represent standard deviation from three
independent measurements.
A242V accepted 10 of 21 sugar nucleo-
tide donors examined, 6 of which were
not detectable substrates of WT OleD,
with improvements in conversion ranging
from 10- to 375-fold (Figure 4B; Table S1).
Proficiency and Promiscuity
A subset of donors (5, 11, 15, 21, and 22),
representing diverse sugar modifica-
tions, was employed to further probe
the donor promiscuity of several OleD
variants by using 1 as the acceptor. The
variants selected included WT, the opti-
mal triple mutant P67T/I112K/A242V (Figure 4B), the previously
described P67T/S132F/A242V (Williams et al., 2007), and the
scaffold for saturation mutagenesis (P67T/I112T/A242V) to rep-
resent a ‘‘family’’ of mutant OleDs with gradual improvements
in proficiency toward the substrate pair 1/5. This analysis re-
vealed that WT OleD accepts only two members of the donor
subset (2 and 11, Figures 4A–4C), whereas the mutant P67T/
S132F/A242V was5-fold improved toward donor 5, slightly en-
hanced with 11, and also accepted 15 (albeit poorly; Figure 4C).
Replacing S132F with I112T in this triple mutant, P67T/S132F/
A242V, further improved activity toward 5, 11, and 15 (Figure 4C).
The final optimal mutant (P67T/I112K/A242V) afforded by satura-
tion mutagenesis displayed further improvements toward 5, 11,
15 and detectable turnover with 22 (Figures 4A–4C). None of the
mutants displayed any detectable activity toward 21.
DISCUSSION
Directed evolution has proven to be an effective tool for altering
the specificity of enzymes and presents a possible solution for
overcoming the strict specificity of certain GTs such as NovM
(Rubin-Pitel and Zhao, 2006). However, the success of directed
evolution is distinctly dependent on the availability of a suitable
high-throughput screen or selection for the desired activity.
This is especially problematic in the context of GTs, given the
huge variety of glycosyl donors and acceptors utilized by this
large family of enzymes (Hu and Walker, 2002; Williams and Thor-
son, 2008b). For example, in the case of novobiocin, the aglycon
1 and any corresponding glycoside (e.g., 7) are indistinguishable396 Chemistry & Biology 15, 393–401, April 2008 ª2008 Elsevier Ltd All rights reserved
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directed evolution of the macrolide GT OleD, based on a simple
fluorescent acceptor surrogate (4), led to the discovery of an
OleD variant that displayed a modest (5-fold) improvement in 1
glucosylation (Williams et al., 2007). This pioneering study served
not only as a potential starting point for circumventing the strin-
gency of the native noviosyltransferase NovM, but it also sug-
gested that the amino acid positions identified (hot spots) as
contributing to GT proficiency and/or promiscuity via the high-
throughput fluorescence-based screen (using 4) may also con-
tribute to utilization of other variant substrates (e.g., 1). Notably,
whereas positions identified by random mutagenesis and screen-
ing/selection for a desired activity have often been further opti-
mized by saturation mutagenesis/recombination (Chica et al.,
2005), the application of the secondary saturation mutagenesis/
recombination to optimize a completely distinct activity (e.g.,
utilization of a very different nonnatural substrate) has not been
reported.
Of the mutations identified in the initial directed evolution study
with fluorescent surrogate 4 (P67T, I112T, S132F, A242V,
G340W; Williams et al., 2007), the first four individually contrib-
uted to improved glycosylation of 1, with I112T as the most active
single mutant. It should be mentioned that, given the low mutation
rates and limited library sizes typically employed in directed
evolution strategies, it is uncommon to find multiple functional
mutations in the same clone. Yet, both P67T and I112T, originally
discovered as a combination in the single clone 8B3, improved
activity with 1. Subsequent combinations of P67T, S132F, and
A242V, on an invariant I112T background, led to catalyst P67T/
I112T/A242V, which displayed a 22-fold improvement in specific
activity toward 1 compared to WT OleD. Saturation mutagenesis
at Pro67, Ile112, and Ala242 on the same background revealed
additional gains via incorporation of polar/charged amino acids
at position 112 (I112T or I112K) and increasing hydrophobic
steric bulk at residue 242 (A242L). In contrast, variation of
Pro67 failed to improve the desired activity under the conditions
employed. Although this preliminary analysis is consistent with
P67T as the optimal substitution, it is also possible that other mu-
tations at Pro67 simply did not improve the rate of glucosylation
at the concentration of acceptor/donor used (i.e., mutations
could improve KM, but not kcat). Interestingly, a final combination
of the optimized mutations (I112K and A242L) was slightly detri-
mental to activity under the assay conditions used, as P67T/
I112K/A242L was less active than both P67T/I112K/A242V and
P67T/I112T/A242L. Yet, the final optimized variant (P67T/
I112K/A242V) displayed a 150-fold improved specific activity to-
ward 1 compared to WT OleD. Steady-state kinetic analysis illus-
trated that P67T/I112K/A242V is 200- or 300-fold more efficient
(in terms of kcat/KM) with UDP-Glc (5) or acceptor 1, respectively,
compared to WT OleD, and this change reflected improvements
in both kcat and KM for donor and acceptor.
Using the high-throughput fluorescence-based ‘‘surrogate’’
screen to first identify functional hot spots notably limited the
low-throughput catalyst optimization to screening only300 col-
onies via HPLC. As a comparison, analysis of the OleD-macrolide
complex structure implicates at least 32 residues (including the
acceptor binding pocket and ‘‘loop N3’’) as being key to forming
the static acceptor binding site (Figure 5) in an ‘‘open’’ conforma-
tion (Bolam et al., 2007). Thus, to simply assess the single bestChemistry & Biologamino acid at each of the 32 structure-designated positions via
saturation mutagenesis would require screening >3000 colonies
(32 3 100 for 95% coverage) by HPLC. Among the hot spots
identified via the fluorescence-based screen, the OleD structure
reveals Ile112 to be intimately associated with acceptor binding
(Figure 5), and the previous mutation of an equivalent residue
(Ile117) in oleandomycin GT OleI (45%identity with OleD) reduced
kcat/KM by100-fold (Bolam et al., 2007). Pro67 is part of the sub-
strate-binding ‘‘loop N3’’ (amino acids 60–76) following b sheet 3
in the N-terminal domain (Figure 5), and a similarly located proline
has been implicated in controlling the substrate specificity of
urdamycin GTs (Hoffmeister et al., 2002). Structural analysis
does not predict the synergistic/antagonistic influences of S132
and/or the A242 optimal substitutions for activity toward 1/5
and may also exclude certain dynamic elements/residues critical
for catalysis. Thus, although both structure-guided and directed-
evolution approaches may ultimately arrive at many of the same
mutations, the hot spot-focused strategy described herein may
present a more streamlined approach for catalyst optimization.
It has been previously suggested that naturally occurring GTs
with high turnover numbers will be more promiscuous (Oberth}ur
et al., 2005). The availability of a unique family of OleD variants
displaying a gradient of catalytic efficiencies from this study
allowed for a more direct test of this hypothesis. As illustrated
in Figure 4C, enhancements in NDP-sugar donor promiscuity
indeed paralleled the improvements in catalyst proficiency, cul-
minating in a catalyst capable of accepting 11 of 21 UDP donors
tested (compared to only trace conversion of 4 UDP donors by
WT OleD). Although this study is consistent with the notion that
more proficient GTs are generally promiscuous, it is also impor-
tant to note that several naturally occurring GTs display very high
efficiency yet remain exquisitely selective. For example, WT
NovM with its natural substrates TDP-L-noviose (2) and 1 is 3
orders of magnitude more proficient than the triple mutant
P67T/I112K/A242V with 1 and 5, based on kcat/KM, but displays
a remarkably narrow substrate specificity range (Freel Meyers
et al., 2003). On the other hand, P67T/I112K/A242V is 1 order
of magnitude more efficient (in terms of kcat/KM toward 1 and
5) than WT NovM toward an alternative donor, TDP-6-deoxy-
glucose (Albermann et al., 2003), and approaches the catalytic
efficiency of other natural-product GTs, such as the relatively
promiscuous teicoplanin GT tGtfb (Howard-Jones et al., 2007).
With respect to the importance of aminocoumarin glycosyla-
tion, the 200-, 300-, and 400-noviose moieties are critical for maintain-
ing the antibacterial activity of 8 (Freitag et al., 2004; Galm et al.,
2004a; Xu et al., 2004), whereas removal of 8, 3-carbamoyl moi-
ety of noviose, increases Hsp90 inhibition R 70-fold (Burlison
et al., 2006; Yu et al., 2005). Glycosyl-modified 8 analogs also
provide potent neuroprotective activities (Ansar et al., 2007).
Yet, although the potential value of varying aminocoumarin gly-
cosylation clearly exists, pathway engineering and semisynthetic
efforts to date have led to fairly conservative glycosyl modifica-
tions (Galm et al., 2004b). The present study sets the stage to
greatly expand upon the availability of differentially glycosylated
aminocoumarins. For example, glucoside 7 and the glycosides
derived from donors 15, 18, 19, 22, 23, 24, and 28 from this proof
of concept study have not been previously described. Access to
these compounds may further the therapeutic development of
aminocoumarins and could also be used to interrogate they 15, 393–401, April 2008 ª2008 Elsevier Ltd All rights reserved 397
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enzymes, such as the acyltransferase CouN7 (Balibar et al.,
2007; Fridman et al., 2007), toward further diversification. Utiliza-
tion of UDP-6-azido-glucose (15) as a new substrate also
presents the potential for further downstream chemoselective
diversification (Fu et al., 2003).
SIGNIFICANCE
Using the macrolide GT OleD as a model, this study unveils
a general enzyme optimization strategy (hot spot saturation
mutagenesis) applicable to reactions limited by amenable
high-throughput screens. Specifically, the application of
a high-throughput screen (based on the fluorescent accep-
tor umbelliferone) was used to identify key amino acid hot
spots that contribute to GT proficiency and/or promiscuity.
Saturation mutagenesis of the corresponding hot spots fa-
cilitated the utilization of a lower-throughput screen (based
on the acceptor novobiocic acid) to provide OleD prodigy
capable of efficiently catalyzing the production of a novel
set of differentially glycosylated aminocoumarins—an im-
portant class of natural products with known antibiotic, an-
ticancer, and antineurodegenerative activities. A systematic
comparison of OleD variants from this study also revealed
the first, to our knowledge, direct correlation between cata-
lyst proficiency and increased donor promiscuity. As this
work demonstrates a platform for the rapid generation of
new glycosylation catalysts, the concept of hot spot satura-
tion mutagenesis as applied herein should be broadly
applicable in the context of new catalyst development.
Figure 5. OleD Active Site Structure
The key residues delineated in this study are highlighted within the previously
reported active site structure of OleD bound to oleandomycin and NDP (PDB
code: 21YF). Color designations—substrates, orange; Pro-67, red; Ile-112,
cyan; Ser-132, magenta; loop N3, yellow; dashed line, H-bond between the
catalytic His-25 and acceptor sugar-OH. Residues in green are those that
form the acceptor binding pocket, which is largely hydrophobic.Chemistry & BiologyEXPERIMENTAL PROCEDURES
General
Bacterial strain E. coli BL21(DE3)pLysS was purchased from Stratagene. No-
vaBlue was purchased from Novagen. Plasmid pET28/OleD was a generous
gift from Professor Hung-Wen Liu (University of Texas-Austin, Austin, USA),
and pET28a was purchased from Novagen. All other chemicals were reagent
grade and were purchased from Fluka, New England Biolabs, or Sigma unless
otherwise stated. Primers were ordered from Integrated DNA Technologies
(Coralville, IA). Novobiocic acid (1) was prepared as previously described
from novobiocin (Albermann et al., 2003). Product standard 4-methyl-umbelli-
feryl-7-O-b-D-glucoside (6) and UDP-Glc (5) were purchased from Sigma.
Analytical HPLC was performed on a Rainin Dynamax SD-2/410 system con-
nected to a Rainin Dynamax UV-DII absorbance detector. Mass spectra were
obtained by using electrospray ionization on an Agilent 1100 HPLC-MSD SL
quadrupole mass spectrometer connected to a UV/Vis diode array detector.
For LC-MS analysis, quenched reaction mixtures were analyzed by analytical
RP-HPLC with a 250 mm3 4.6 mm Gemini 5mC18 column (Phenomenex, Tor-
rance, CA) by using a gradient of 10%–90% CH3CN in 0.1% formic acid/H2O
for 20 min at 1 ml/min, with detection at 254 nm. Structural characterization
was performed by NMR spectroscopy using a Varian UNITYINOVA 500 MHz
instrument (Palo Alto, CA) in conjunction with a Protasis/MRM CapNMR
capillary probe (Savoy, IL). The spectrum was referenced to DMSO-d6 at
2.50 ppm.
Site-Directed Mutagenesis
Site-specific OleD variants were constructed by using the Stratagene
QuikChange II Site-Directed Mutagenesis Kit, as described by the manufac-
turer. Constructs were confirmed to carry the correct mutation(s) via DNA
sequencing.
Saturation Library Preparation
The saturation mutagenesis libraries ‘‘P67X,’’ ‘‘I112X,’’ and ‘‘A242X’’ were con-
structed by using the Stratagene QuikChange II Site-Directed Mutagenesis Kit,
as described by the manufacturer, with the mutant P67T/I112T/A242V as tem-
plate. For each library, plasmid DNA (digested with DpnI) was transformed into
Novablue chemical competent cells, and the transformants were grown over-
night at 37C on LB agar supplemented with 50 mg/ml kanamycin. Colonies
from each library were subsequently pooled and used to inoculate 5 ml LB me-
dium supplemented with 50 mg/ml kanamycin for overnight growth at 37C
with shaking (350 rpm). Using standard mini-prep purification, the mixed-pop-
ulation plasmid prep was prepared from each 5 ml culture and transformed
into E. coli BL21(DE3)pLysS, and the transformants were grown overnight at
37C on LB agar supplemented with 50 mg/ml kanamycin.
For protein expression, individual colonies from plates containing
BL21(DE3)pLysS transformants were subsequently used to inoculate wells
of a 96-deep well microtiter plate, wherein each well contained 1 ml LB me-
dium supplemented with 50 mg/ml kanamycin. Culture plates were tightly
sealed with AeraSeal breathable film (Research Products International
Corp.). After cell growth at 37C for 18 hr with shaking at 350 rpm, 100 ml of
each culture was transferred to a fresh deep-well plate containing 1 ml LB me-
dium supplemented with 50 mg/ml kanamycin. The original plate was sealed
and stored at 4C, or a glycerol copy was made by mixing 100 ml of each cul-
ture with 100 ml 50% (v/v) glycerol and was stored at 80C. The freshly inoc-
ulated plate was incubated at 37C for 2–3 hr with shaking at 350 rpm. Protein
expression was induced at an OD600 of 0.7, isopropyl b-D-thiogalactoside
(IPTG) was added to a final concentration of 0.4 mM, and the plate was incu-
bated for 18 hr at 18C. Cells were harvested by centrifugation at 30003 g for
10 min at 4C, the cell pellets were thoroughly resuspended in chilled 50 mM
Tris-HCl (pH 8.0) containing 10 mg/ml lysozyme (Sigma), and the plates wereFigure 4. Probing the Donor Specificity of WT OleD and Mutant Prodigy
(A) The set of UDP-sugar donors used to probe specificity. Dashed-boxed donors were detectable substrates for both WT and mutant P67T/I112T/A242V OleD,
whereas solid-boxed donors were substrates only for P67T/I112T/A242V.
(B) Successful conversion rates (%) after 3 hr with WT or P67T/I112T/A242V OleD by using 50 mM acceptor 1 and 250 mM UDP-sugar donors (the reactions
containing 28 were incubated for 18 hr).
(C) Improvement of donor promiscuity with increasing proficiency of OleD variants.15, 393–401, April 2008 ª2008 Elsevier Ltd All rights reserved 399
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‘‘Hot Spot’’ Mutagenesis of Glycosyltransferasessubjected to a single freeze/thaw cycle to lyse the cells. After thawing, cell
debris was collected by centrifugation at 30003 g for 20 min at 4C, and 50 ml
of the cleared supernatant was used for the enzyme assay.
For crude extract assays, cleared supernatant was mixed with an equal vol-
ume (50 ml) of 50 mM Tris-HCl (pH 8.0) containing 10 mM MgCl2, 200 mM 1, and
1.0 mM 5 by using a Biomek FX Liquid Handling Workstation (Beckman Coul-
ter, Fullerton, CA). Upon mixing, the reactions were incubated for 3 hr at 30C,
at which point the crude reaction mixture was mixed with an equal volume of
MeOH and centrifuged at 30003 g for 20 min at 4C. Aliquots of each product
mixture (40 ml) were analyzed by RP-HPLC as described below for
determination of specific activity.
Protein Expression and Purification
For the characterization of specific OleD variants, single colonies were used to
inoculate 3 ml LB medium supplemented with 50 mg/ml kanamycin and were
cultured overnight at 37C. The entire starter culture was then transferred to
1 l LB medium supplemented with 50 mg/ml kanamycin and were grown at
37C until the OD600 was 0.7, IPTG to a final concentration of 0.4 mM was
added, and the flask was incubated for 18 hr at 18C. Cell pellets were col-
lected by centrifugation at 10,000 3 g and 4C for 20 min; resuspended in
10 ml 20 mM phosphate buffer (pH 7.4), containing 0.5 M NaCl and 10 mM
imidazole; and were lysed by sonication. Cell debris was removed by centrifu-
gation at 10,0003 g at 4C for 30 min, and the cleared supernatant was imme-
diately applied to 2 ml nickel-nitrilotriacetic acid (Ni-NTA) resin (QIAgen Valen-
cia, CA), pre-equilibrated with lysis buffer. Protein was allowed to bind for
30 min at 4C with gentle agitation, and the resin was washed four times
with 50 ml lysis buffer. Finally, the enzyme was eluted by incubation of the resin
with 2 ml lysis buffer containing 100 mM imidazole for 10 min at 4C with gentle
agitation. The purified enzyme was applied to a PD-10 desalting column
(Amersham Biosciences AB) equilibrated with 50 mM Tris-HCl (pH 8.0) and
eluted as described by the manufacturer. Protein aliquots were immediately
flash frozen in liquid nitrogen and stored at 80C. Protein purity was verified
by SDS-PAGE. Protein quantification was carried out by using the Bradford
Protein Assay (Bio-Rad, Hercules, CA).
Determination of Specific Activity with 1 or 4 as Acceptor
Enzyme reactions were carried out in a total volume of 100 ml 50 mM Tris-HCl
(pH8.0) containing 5 mM MgCl2, 200 mM 1 or 4, 5 mM 5, and, typically, 10–50
mg pure enzyme. At a suitable time interval during which the rate of product for-
mation was linear with time (typically 2–20 min), reactions were quenched with
100 ml MeOH, and the samples were centrifuged at 10,000 3 g for 10 min.
Supernatants were analyzed by analytical RP-HPLC with a Gemini 5m C18 col-
umn (Phenomenex) by using a gradient of 10%–90% CH3CN in 0.1% trifluoro-
acetic acid (TFA)/H2O for 20 min, with detection at 254 nm. Under these con-
ditions, substrates 1 (tR = 25.5 min) or 4 (tR = 14.5 min) and the glucoside
products 7 (tR = 18.8 min) or 6 (tR = 9.95 min) were readily resolved. The identity
of 7 was confirmed by LC-MS and NMR, whereas the density of glucoside 6
was confirmed by coelution with a commercial standard and LC-MS analysis.
HPLC peak areas were integrated, and the product concentrations were cal-
culated as a percentage of the total peak area. Specific activity was expressed
as nanomoles product formed/min/mg protein.
Scale-Up and Characterization of Glucoside 7
The preparative reaction to synthesize the novobiocyl glucoside (7) was
accomplished at room temperature in a total volume of 10 ml in 50 mM
Tris-HCl (pH 8.0) containing 5 mM MgCl2, 10 mg novobiocic acid (1), 60 mg
UDP-Glc (5), and 5 mg purified OleD mutant P67T/I112T/A242V. The reaction
was incubated for 48 hr, after which protein was removed by adding 30 ml cold
MeOH and by centrifugation at 10,0003 g and 4C for 30 min. The supernatant
was concentrated, lyophilized, and resuspended in 1 ml DMSO, and the sam-
ple was purified by HPLC by using a Gemini 5mC18 column (Phenomenex) with
a gradient of 10%–90% CH3CN in 0.1% trifluoroacetic acid (TFA)/H2O for 20
min, with detection at 254 nm. The product fractions were pooled and lyoph-
ilized. 1H NMR (1:2 DMSO-d6:CD3OD) d7.69 (br s, 1 H, H5
00), 7.66 (br s, 1 H, H2),
7.50 (m, 1 H, H6), 7.09 (br d, J = 7.1 Hz, 1 H, H6
0), 6.69 (m, 1 H, H5), 5.24 (br s, 1
H, H8), 4.90 (d, J = 6.9 Hz, 1 H, H1
00), 3.75 (d, J= 11.5 Hz, 1 H, H6a00), 3.56 (m, 1 H,
H6b
00), 3.36 (m, 4 H, H200-500), 3.27 (m, 2 H, H7), 2.09 (s, 3 H, H110), 1.62 (s, 6 H,400 Chemistry & Biology 15, 393–401, April 2008 ª2008 Elsevier LtdH10,11). The anomeric coupling constant and NOESY are consistent with the
C7-b-glucoside (7) (see Figure S1).
Determination of Kinetic Parameters
Enzyme assays were carried out in a total volume of 100 ml 50 mM Tris-HCl (pH
8.0) containing 5 mM MgCl2 and, typically, 10–50 mg pure enzyme. Kinetic
parameters kcat and KM were determined with both 1 and 5 as variable sub-
strates. For the determination of KM for 1, 5was constant at 5 mM and 1 varied
between 0.025 and 5 mM. For the determination of KM for 5, 1 was constant at
5 mM and 5 varied between 0.05 and 25 mM. Each experiment was performed
in triplicate. Aliquots (100 ml) were removed between 0 and 30 min, at which
time product formation was still linear with respect to time; quenched with
100 ml ice-cold MeOH, and centrifuged at 10,0003 g for 10 min. Supernatants
were analyzed by analytical RP-HPLC as described above. The substrate 1
and the glucoside product 7 HPLC peak areas were integrated, and the prod-
uct concentration was calculated as a percent of the total peak area. Initial
velocities were fitted to the Michaelis-Menten equation by using Sigma Plot.
Donor Specificity
To assess donor specificity, assays contained 50 mM acceptor 1 and500 mM
putative NDP-sugar donor in a total assay volume of 50 ml. For this study, the
NDP sugars were used directly from RmlA-catalyzed reactions (Barton et al.,
2002; Fu et al., 2003; Jiang et al., 2003). Although 11, 14, and 24 were also
commercially available, low levels of contamination with UDP-Glc in the com-
mercial reagents complicated product analysis by LC-MS (data not shown),
and, therefore, the RmlA-derived 11, 14, and 24 were utilized. Reactions
were incubated at 25C for 3 hr. Aliquots (25 ml) were quenched with 25 ml
ice-cold MeOH and were centrifuged at 10,000 3 g for 10 min. Supernatants
were analyzed by analytical RP-HPLC as described above. HPLC peak areas
were integrated, and the product concentration was calculated as a percent of
the total peak area. All products were characterized by LC-MS.
SUPPLEMENTAL DATA
Supplemental Data include NOESY of novobiocic acid glucoside 7 and
RP-HPLC/LC-MS analysis of WT and mutant OleD donor specificity and are
available at http://www.chembiol.com/cgi/content/full/15/4/393/DC1/.
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